The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
1
1
2
Edited News | UNMAS
Demining experts from around the world have been sharing their collective shock at the widespread and growing threat from unexploded ordnance, the new head of the UN Mine Action Service (UNMAS) said on Wednesday.
1
1
1
Edited News | OHCHR , UNOG
The UN Human Rights Office in Syria conducted a 5-day visit to the northeast of the country where they received accounts of human rights violations and abuses.
1
1
1
Edited News | UNICEF
Sudan: ‘History repeating itself’ for Darfur’s children - UNICEF
Mass atrocities in Sudan’s Darfur 20 years ago reverberated as far as Hollywood, but today, a new generation of children faces attacks, hunger and displacement in an emergency largely ignored by the outside world, the UN Children’s Fund (UNICEF) warned on Tuesday.
1
1
Edited News | WHO , UNMAS
Desperate and dangerous conditions in Gaza continue to hamper recovery efforts for the wartorn enclave's people, the UN health agency said on Friday, while demining experts warned that they’ve “barely scratched the surface” in assessing the level of contamination of unexploded ordnance.
2
1
2
Press Conferences , Edited News
The continued support of UN Member States to Lebanon will be “indispensable” to boost the country’s national armed forces and provide humanitarian assistance with more than one million people still uprooted by the Middle East war, the UN's peacekeeping chief said on Wednesday.
2
1
2
Press Conferences , Edited News | UNECE
Middle East war: After oil and gas shortages, concerns grow over critical minerals crunch
The shipping crisis in the Strait of Hormuz caused by war in the Middle East has exposed a new threat: a looming shortage of strategic minerals needed to drive economies all over the world and a race by countries to obtain them.
1
1
1
Edited News | IOM
Millions of desperate Sudanese return home amid dire conditions as war rages – IOM
Three years into the devastating conflict in Sudan, nearly four million displaced people have returned to their places of origin across the country, only to face “another struggle for survival”, the UN International Organization for Migration (IOM) said on Tuesday.
1
1
1
Edited News | UNESCO
UNESCO protects cultural sites in war-torn Middle East, confirming damage to key heritage.
1
1
1
Edited News | UN WOMEN
The war in Gaza has inflicted a far higher toll on women and girls than in previous conflicts in the Palestinian enclave, with more than 38,000 killed by Israeli air bombardment and land military operations since Hamas-led terror attacks in Israel sparked the war in October 2023, UN Women said on Friday.
1
1
1
Edited News | UNHCR
In 2025, nearly 900 Rohingya refugees were reported missing or dead in the Andaman Sea and Bay of Bengal, making it the deadliest year on record in South and Southeast Asia, the UN refugee agency, UNHCR, said on Friday.
1
1
1
Edited News | UNFPA , IFRC
Lebanon faces escalating violence, with new mothers uncertain of safety amid ongoing crises.
1
1
1
Edited News | FAO , UNHCR , WHO
Sudan: 14 million displaced; hunger and attacks on health continue as war enters fourth year
As Sudan approaches the third anniversary of a brutal civil war, millions remain displaced and hungry while the health system lies in ruins, with no end to the violence in sight, UN agencies said on Friday.